CaMMouflage
A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)
Filters
Save & Share
Clear Filters
Location
Explore options near your patient - or anywhere in the US.
Diagnosis
Treatment History
BCMA Therapy
This stands for B Cell Maturation Antigen (BCMA) and includes treatments such as ide-cel, cilta-cel or belantamab mafodotin.
Near Add Your Location
Sorting 17 by
Memorial Sloan Kettering Cancer Center
New York, NY
- Accepting patients
- Show Principal Investigator
- Accepting patients
- Show Principal Investigator
- Accepting patients
- Show Principal Investigator
- Accepting patients
- Show Principal Investigator
Oncology Hematology Care Inc. (Kenwood)
Cincinnati, OH
- Accepting patients
- Accepting patients
- Show Principal Investigator
- Accepting patients
- Show Principal Investigator
Virginia Commonwealth University Medical Center
Richmond, VA
- Accepting patients
- Accepting patients
- Show Principal Investigator
- Accepting patients
- Show Principal Investigator
1,357 hidden based on your filters. Show All
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.